In group A (long-term survivors of lymphoma who underwent MI/DCI therapy, Table 1), a significant reduction after 12 months was observed for FSH (p = 0.0199), LH (p = 0.0219), and oligomenorrhea (p < 0.0001) and a reduction in the limits of statistical significance for PG level (p = 0.0501); in addition, the AFC of the right ovary at T12 increased significantly (p = 0.0055). This evidence concerns the gene BRD2 and lymphoma.